Sustained and focused hepatitis B virus nucleocapsid–specific T‐cell immunity in liver transplant recipients compared to individuals with chronic and self‐limited hepatitis B virus infection
Florian Bihl, Elisabetta Loggi, John V. Chisholm, Maurizio Biselli, Maria C. Morelli, Carmela Cursaro, Norah A. Terrault, Mauro Bernardi, Antonio Bertoletti, Pietro Andreone, Christian Brander – 6 March 2008 – Hepatitis B virus (HBV) recurrence after orthotopic liver transplantation (OLT) is associated with poor graft‐ and patient‐survival. Treatment with HBV‐specific immunoglobulins (HBIG) in combination with nucleos(t)ide analogs is effective in preventing HBV reinfection of the graft and improving OLT outcome.